Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
COMPLETED
NCT06438757
PHASE2
Trial of JYB1904 in Patients With Allergic Asthma
Sponsor: Jemincare
View on ClinicalTrials.gov
Summary
This phase IIa trial is meant to evaluate the pharmacokinetics, pharmacodynamics and safety of JYB1904 in patients with allergic asthma.
Official title: Phase IIa Trial to Evaluate the Pharmacokinetic/Pharmacodynamic Characteristics and Safety of JYB1904 in Patients With Allergic Asthma
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
69
Start Date
2024-06-19
Completion Date
2025-12-20
Last Updated
2026-06-15
Healthy Volunteers
No
Conditions
Interventions
DRUG
JYB1904
Participants will receive JYB1904 every 8 weeks for 24 weeks.
DRUG
Omalizumab
Participants will receive Omalizumab every 2/4 weeks for 24 weeks.
Locations (1)
Shanghai General Hospital
Shanghai, Shanghai Municipality, China